Substance use disorders identification

Screening
Among the best clinical settings for early screening, detection and intervention of substance use disorders are primary care offices, trauma centers, and emergency rooms. Members with positive screens obtained through any of the following methods should be further evaluated. For the initial screening, the primary care or other clinician can:

- **Administer a substance use screening tool**, such as the Alcohol Use Disorders Identification Test (AUDIT), AUDIT-C (Consumption) or the CAGE-AID. The first three questions of the AUDIT can be used alone to detect up to 80 percent of patients with mild to moderate alcohol use problems. The Audit-C, a three-item modified version of the AUDIT instrument, screens for frequency of alcohol consumption, quantity of alcohol consumption, and the quantity of alcohol consumption on a single occurrence. The four-item CAGE alcohol use questionnaire is the most popular screening test used in primary care. The CAGE-AID expands the focus of each item of the CAGE to include both alcohol and other drugs and identifies severe alcohol and drug use problems, including dependence. (AUDIT and CAGE can be accessed at http://pubs.niaaa.nih.gov/publications/aa65/AA65.htm.)
- **Administer a single-question screen**: “When was the last time you had more than four drinks (women) or five drinks (men) in one day?” Up to 86 percent of those with alcohol-use problems can be identified with this question. A positive result is “one or more times in the past three months.”
- **Look for warning signs suggesting substance use disorders**, including repeated complaints of physical discomfort, elevated vital signs, frequent accidents, sleep disturbances, fatigue and unintentional weight loss.
- **Assessing adolescents**: Signs of substance use disorders in adolescents may include involvement in the juvenile justice system, truancy or poor grades, diminished interests in hobbies or sports, irritability, lying, carelessness about appearance, family conflict, injuries requiring emergency room visits, etc. When alcohol use is a problem in adolescents, illegal drug use is 11 times more likely to also be a problem. The CRAFFT test was developed specifically for screening adolescents. (Access at http://www.netwellness.org/healthtopics/substanceabuse/crafft.cfm.)
- **Assessing older adults**: Substance use disorders in older adults are under-diagnosed. One in three older adults who abuse alcohol develops the problem after age 60. Older adults require less alcohol to become intoxicated, and can easily hide problematic alcohol use due to lower demands for social and occupational functioning.
Treatment

- A recent systematic review and meta-analysis for the U.S. Preventive Services Task Force found that behavioral counseling interventions improve alcohol consumption with brief multicontact interventions (i.e., 10-15 minute per contact) delivered by a primary care provider, a nurse or health educator. In another study, a single discussion on the risks of alcohol abuse, goal setting for cutting back, and one follow-up discussion reduced alcohol consumption by 30 percent and occasions of binge-drinking over a 12-month period.  
- Pharmacotherapy interventions can be helpful during all phases of treatment (see Table). Medications are best used in combination with psychotherapy or counseling interventions. Medication-Assisted Treatment (MAT) has been shown to be effective in the treatment of alcohol dependence with Food and Drug Administration (FDA)-approved drugs (e.g., disulfiram, naltrexone, acamprosate) and treatment of opioid dependence with methadone, naltrexone and buprenorphine.  
- For adolescents and patients on methadone maintenance, family therapy has demonstrated effectiveness.  
- Psychosocial treatment emphasizing social support is effective for older adults at risk of relapse due to loneliness and social isolation.  
- Self-help groups such as Alcoholics Anonymous (www.alcoholics-anonymous.org), Narcotics Anonymous (www.na.org) and Al-anon (www.al-anon.alateen.org) can be helpful.

References

# Pharmacotherapy for Substance Use Disorders

<table>
<thead>
<tr>
<th>Name</th>
<th>Indications</th>
<th>Prescribing <em>(Starting dose, range, baseline labs)</em></th>
<th>Advantages</th>
<th>Risks</th>
</tr>
</thead>
</table>
| **Disulfiram** *(Antabuse)* | Helps prevent relapse of alcohol abuse. Ingested in combination with alcohol, it causes nausea, vomiting, headache and flushing. | **Induction:** 250-500 mg QD for 2 weeks.  
**Maintenance:** 250 mg QD. Range is 125-500mg QD.  
**Labs:** liver function tests (LFT)s initially, then at 10-14 days, every six months thereafter. | Useful in patients with a history of relapse, current motivation, and a witnessed ingestion program | Metallic after-taste; dermatitis; severe reaction or death could result from alcohol ingestion |
| **Naltrexone** *(Revia)*  
**Vivitrol™** *(naltrexone for extended-release injectable suspension)* | Helps with alcohol cravings, possibly by reducing the reinforcing effects of alcohol. Also used to block the effects of opiates.  
Vivitrol™ is used for the treatment of alcohol dependence and for the prevention of relapse following opioid detoxification. | **Induction for opiate dependence:** Be sure patient is opioid-free for 7-10 days; confirm by urine drug screen (UDS). Start 25 mg. If no withdrawal reaction, increase by another 25 mg. Continue at 50 mg QD.  
**Induction for alcohol dependence:** Start at 50 mg QD. Continue at 50 mg QD.  
**Vivitrol™:** Be sure patient is alcohol-free for at least a week. IM dose – 380 mg q 4 weeks.  
**Labs:** UDS, LFTs prior to induction and every six months thereafter. | Very useful in the acute recovery phase of alcohol dependence (first 12 weeks).  
Vivitrol™ may be easier for patients recovering from alcohol dependence to use consistently. The once-monthly formulation addresses the critical problem of adherence in the opioid addicted population. Also addresses problems encountered with substitution therapy – i.e., access, acceptability, diversion, illicit use and overdose deaths. | Nausea; abdominal pain; constipation; dizziness; headache; anxiety; fatigue.  
Vivitrol™ should not be used by a patient who is also using opioids such as heroin or opioid analgesics. |
| **Acamprosate** *(Campral)* | Helps with alcohol cravings, possibly by reducing intensity of prolonged withdrawal syndrome. Benefit emerges after 30 to 90 days. | **Induction:** Begin two 333 mg tablets, tid. Patients with renal impairment may need dosage reduction.  
**Maintenance:** 333 mg, tid.  
**Labs:** blood urea nitrogen (BUN), creatinine, creatinine-clearance. | Reasonably safe in patients with mild to moderate hepatic impairment (excreted via the kidneys). | Diarrhea and increased libido. |
<table>
<thead>
<tr>
<th>Name</th>
<th>Indications</th>
<th>Prescribing</th>
<th>Advantages</th>
<th>Risks</th>
</tr>
</thead>
</table>
| **Topiramate (Topamax)**          | Helps patients reduce drinking, avoid relapse to heavy drinking, achieve and maintain abstinence, or gain a combination of these effects. (Note: the FDA has not approved the drug for this indication.) | **Induction:** Initial dose 25 mg at bedtime. Increase dose by 25-50 mg daily each week, divided into morning and evening doses.  
**Maintenance:** Target dose is 200 mg per day total, but patients unable to tolerate that dose may respond to lower doses.  
**Labs:** Monitor renal function, serum electrolytes and bicarbonate. | Can be used in patients who are still drinking. | Paresthesias; taste perversion; anorexia and weight loss; somnolence; cognitive dysfunction. |
| **Baclofen (Lioresal, Kemstro)**  | Baclofen has shown promise in initial clinical trials for treating severe alcohol dependence. Baclofen is administered to patients who have already become abstinent.  
There is also some empirical evidence that baclofen is comparable to diazepam in reducing uncomplicated alcohol withdrawal symptoms. | **Induction:** Begin 5 mg tid for the first three days and then to a ceiling dosage of 10 mg tid.  
**Maintenance:** Continue 10 mg tid.  
**Labs:** aspartate aminotransferase (AST), alkaline phosphatase or glucose levels for patients with liver diseases or diabetes mellitus. | Particularly well suited for patients with liver impairment as it is excreted primarily through the kidney. | Common adverse side effects: headaches, insomnia, nausea, hypotension, urinary frequency. Rare side effects include visual abnormalities and excitement. |
| **Buprenorphine Hydrochloride (Subutex)** | Can be used for office-based detoxification from opiates and maintenance treatment for opiate dependency by specially trained and registered physicians. | **Induction:** Begin 8 mg SL on day one, 16 mg day two.  
**Maintenance:** Continue 16 mg SL QD thereafter. Range is 4-24 mg QD.  
**Labs:** UDS at induction, and monthly thereafter. LFTs on induction, every six months thereafter. | Buprenorphine can prevent symptoms of withdrawal in patients addicted to opiates; an alternative maintenance treatment to methadone. | Dizziness; nausea; respiratory depression. |


These guidelines are not intended to replace a practitioner’s clinical judgment. They are designed to provide information and to assist practitioners with decisions regarding care. The guidelines are not intended to define a standard of care or exclusive course of treatment. Health care practitioners using these guidelines are responsible for considering their patients’ particular situation in evaluating the appropriateness of these guidelines.

This information is not a statement of benefits. Benefits may vary and individual coverage will need to be verified by the Plan.